# Alto Neuroscience, Inc. (ANRO) — capital_raise/public_offering [pending]
Source: SEC API (secapi.ai) · situation sit_6124c541ef104b6b428c · retrieved 2026-08-11T16:11:13.995Z

## Overview
Alto Neuroscience, Inc. is a pharmaceutical company developing ALTO-207, a product candidate for the treatment of treatment-resistant depression, with clinical development programs including Phase 3 trials.

Alto Neuroscience, Inc. entered into an underwriting agreement with BofA Securities, Inc. and other underwriters on July 13, 2026, to issue and sell 3,776,436 shares of common stock at $26.48 per share in an underwritten registered direct offering. The company estimates net proceeds of approximately $93.9 million after deducting underwriting discounts, commissions, and estimated offering expenses. The closing is expected to occur on July 14, 2026, subject to customary closing conditions. The company intends to use the net proceeds, together with its current cash and cash equivalents, to accelerate and expand the clinical development of ALTO-207, including to conduct an additional planned Phase 3 trial of ALTO-207 as monotherapy for the treatment of treatment-resistant depression, and for general working capital purposes.

## Terms
- Counterparty: BofA Securities, Inc. and other underwriters · Consideration: cash · Price/share: $26.48

## Key dates
- Expected close 2026-07-14

## Timeline
- 2026-07-14 · 8-K (0001104659-26-083274): 8-K - Alto Neuroscience, Inc. — *Alto Neuroscience, Inc. is a pharmaceutical company developing ALTO-207, a product candidate for the treatment of treatment-resistant depression, with clinical development programs including Phase 3 trials.* Alto Neuroscience, Inc. entered into an underwriting agreement with BofA Securities, Inc. and other underwriters on July 13, 2026, to issue and sell 3,776,436 shares of common stock at $26.48 per share in an underwritten registered direct offering. The company estimates net proceeds of approximately $93.9 million after deducting underwriting discounts, commissions, and estimated offering expenses. The closing is expected to occur on July 14, 2026, subject to customary closing conditions. The company intends to use the net proceeds, together with its current cash and cash equivalents, to accelerate and expand the clinical development of ALTO-207, including to conduct an additional planned Phase 3 trial of ALTO-207 as monotherapy for the treatment of treatment-resistant depression, and for general working capital purposes.
  https://www.sec.gov/Archives/edgar/data/1999480/0001104659-26-083274.txt

## Citations
- 0001104659-26-083274 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926083274